Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- T-DM1 + Pertuzumab Effective for HER2-Positive Breast Cancer
June 21, 2010
- Benefit-Sharing Based on CBD May Affect Pharma Industry
June 21, 2010
- Roche's Hedgehog Inhibitor Safe in Combination with Standard Chemotherapy
June 21, 2010
- Korosho Issues Memo to Clarify Requirements for Applicants
June 21, 2010
- Avastin Prolongs PFS, but Not OS in PIII in Stomach Cancer
June 21, 2010
- DSP Applies for Changes in Maximum Daily Dose for Meropen
June 21, 2010
- Avastin Effective for HER2-Negative Breast Cancer in Japanese Patients
June 21, 2010
- Add Prevenar to Routine Vaccination Programs in Japan: Mr Kindler
June 21, 2010
- Eribulin Receives Priority Review Status in the US
June 21, 2010
- Erbitux + FOLFIRI Effective for Stomach Cancer in PII
June 21, 2010
- Pfizer, Eisai Launch Lyrica
June 21, 2010
- GL for Non-Clinical Evaluation of Anti-Malignant Tumor Agents Issued
June 21, 2010
- Eplerenone Meets Primary Endpoint Early in PIIIb: Pfizer
June 21, 2010
- Bayer to Expand Packing Line for Chewable Tablets
June 21, 2010
- Clinical Trial Costs Can Be Cut Using iPad: Mr Hasegawa
June 21, 2010
- Lubiprostone Meets Primary Endpoint in PIII in Japan
June 21, 2010
- Asahi Kasei's Pharm Sales to Fall below Target Set in Mid-Term Management Plan
June 21, 2010
- New OTC Drugs Consultation Services Started
June 21, 2010
- Diovan Shows Hypotensive Effects in Elderly Japanese Patients
June 21, 2010
- Rezaltas No. 1 in Both HP, GP Market
June 21, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…